Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2337-2346

  Buchacz, Kate ^a   Young, Benjamin ^b,c   Palella, Frank J ^d,f   Armon, Carl ^e   Brooks, John T ^a   Durham, Marcus D ^a   Hays, Harlen ^e   Wood, Kathleen C ^e   Hankerson, Darlene ^e   Hart, Rachel ^e   Subramanian, Thilakavathy ^e   Dean, Bonnie ^e   Franklin, Dana ^e   Chmiel, Joan S ^f   Jahangir, Saira ^f   Flaherty, Conor Daniel ^f   Dixon Evans, Jerian Denise ^g   Lichtenstein, Kenneth A ^g   Stewart, Cheryl ^g   Hammer, John ^h   Greenberg, Kenneth S ^h   Widick, Barbara ^b,h   Franklin, Rosa ^h   Yangco, Bienvenido G ⁱ   Chagaris, Kalliope ⁱ   Ward, Doug ^j   Fuhrer, Jack ^k   Ording Bauer, Linda ^k   Kelly, Rita ^k   Esteves, Jane ^k   Tedaldi, Ellen M ^l   Christian, Ramona A ^l   Ruley, Faye ^l   Beadle, Dania ^l   Graham, Princess ^l   Novak, Richard M ^m   Wendrow, Andrea ^m   Smith, Renata ^m   Scott, Mia ^b   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Apex Family Medicine and Research   (United States)

^c INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CERNER CORPORATION   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g DEPARTMENT OF MEDICINE   (United States)

^h ROSE MEDICAL CENTER   (United States)

ⁱ INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^j Troy Thomas Dupont Circle Physicians Group   (United States)

^k STONY BROOK UNIVERSITY   (United States)

^l TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Epidemiology; Genotype; HIV infection; Mutation; Primary; Transmitted

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; NONHUMAN; OUTPATIENT; PRACTICE GUIDELINE; AGED; ANTIVIRAL RESISTANCE; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; UNITED STATES; UTILIZATION; VIROLOGY;

ADULT; AGED; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84939558244     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv120     Document Type: Article

References (37)

1. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59: 1047-56.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Issue: May 4, 2006. http://aidsinfo.nih.gov/guidelines/archive/adult-and-adolescent-guidelines.
3. Ocfemia C, Saduvala N, Oster A et al. Transmitted HIV-1 drug resistance among men who have sex with men-11 U.S. jurisdictions, 2008-2011. In: Abstracts of the Twenty-first Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014. Abstract 579. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
4. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 2002; 347: 385-94.
5. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-80.
6. Torian LV, Forgione LA. Transmitted antiretroviral drug resistance in New York City, 2006-2010: the first five years of routine genotype surveillance. J Acquir Immune Defic Syndr 2013; 63: e119-22.
7. Wheeler WH, Ziebell RA, Zabina H et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, US-2006. AIDS 2010; 24: 1203-12.
8. Kim D, Ziebell R, Saduvala N et al. Trends in transmitted HIV-1 antiretroviral drug resistance-associated mutations, 10 U.S. HIV surveillance areas, 2007-2010. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 149. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
9. Castor D, Low A, Evering T et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 2012; 61: 1-8.
10. Jain V, Liegler T, Vittinghoff E et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010; 5: e15510.
11. Johnson JA, Li J-F, Wei X et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: 1112-22.
12. Poon AFY, Aldous JL, Mathews WCet al. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One 2011; 6: e21189.
13. Gagliardo C, Brozovich A, Birnbaum J et al. A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City. Clin Infect Dis 2014; 58: 865-72.
14. Baxter J, Dunn D, White E et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 Suppl 1: 77-87.
15. Yanik EL, Napravnik S, Hurt CB et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61: 258-62.
16. Truong H-HM, Kellogg TA, McFarland W et al. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent Infection. PLoS One 2011; 6: e25281.
17. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004; 9: 695-702.
18. Wang Z, Walits E, Gordon DE et al. Transmitted drug resistance and time of HIV infection, New York State, 2006-2013. In: Abstracts of the Twenty-second Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015. Abstract 599. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
19. Descamps D, Assoumou L, Chaix M-L et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013; 68: 2626-31.
20. Burchell AN, Bayoumi AM, Rourke SB et al. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-2009. J Antimicrob Chemother 2012; 67: 2755-65.
21. Yerly S, von Wyl V, Ledergerber B et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21: 2223-9.
22. Dolling D, Sabin C, Delpech V et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345: e5253.
23. Frentz D, Boucher CAB, van de Vijver DAMC. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14: 17-27.
24. Olson A, Kucherer C, Sonnerborg A et al. Temporal trends of transmitted HIV drug resistance following seroconversion. In: Abstracts of the Twenty-second Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015. Abstract 602. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
25. Wittkop L, Guenthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
26. Buchacz K, Baker R, Ward DJ et al. Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV Outpatient Study: 1999-2008. AIDS Res Treat 2012; 2012: 230290.
27. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
28. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
29. Novak RM, Debes R, Chmiel J et al. Disparities in initiation of HAARTand in virologic suppression among patients in the HIV Outpatient Study (HOPS), 2000-2010. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 1032A. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Issue: December 1, 2007. http://aidsinfo.nih.gov/guidelines/archive/adult-andadolescent-guidelines.
31. De Cock KM, El-Sadr WM. When to start ART in Africa-An urgent research priority. New Engl J Med 2013; 368: 886-9.
32. Cong M-e, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81: 3037-41.
33. CDC. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep 2013; 62: 463-5.
34. Castro H, Pillay D, Cane P et al. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208: 1459-63.
35. Ragonnet-Cronin M, Lee BE, Plitt SS et al. Baseline clinical HIV genotypes are a valid measure of transmitted drug resistance within the treatmentnaive population. J Acquir Immune Defic Syndr 2013; 64: 443-7.
36. Young B, Fransen S, Greenberg KS et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16: 253-6.
37. Masquelier BND, Bhaskaran K, Deenan P et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms-Data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40: 505-11.